What is Rapport Therapeutics, Inc.'s change in AR?

Rapport Therapeutics, Inc. (RAPP) reported change in AR of $58K in Q1 2026.

What does change in AR mean?

Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.

Rapport Therapeutics, Inc. RAPP Change in AR

Change in AR at other companies

Supernus PharmaceuticalsSUPN

-$5.62M-258%

Septerna, Inc.SEPN

$486K+515%

Acadia PharmaceuticalsACAD

$13.89M+98.4%

Catalyst PharmaceuticalCPRX

$4.36M-24.7%

Arrowhead ResearchARWR

$212.05M+8,382%

Crinetics PharmaceuticalsCRNX

$5.09M—

Other financials

Income statement

See full

Revenue$20.0M—

Operating income-$24.2M+10.7%

Net income-$19.9M+17.5%

EPS (diluted)-$0.42+38.2%

Balance sheet

See full

Cash & equivalents$78.1M+35.5%

Total debt$10.8M+37.8%

Total equity$471.5M+65.0%

Total assets$497.6M+64.7%

Cash flow

See full

Operating cash flow-$13.1M+35.5%

CapEx$86.0K-70.4%

Free cash flow-$13.1M+36.0%

Valuation

See full

Market cap$1.91B+309%

Returns & leverage

See full

Return on equity-28.3%—

Debt / equity0×0.0×

Current ratio27.1×-3.9×

Where this comes from

Reported directly by Rapport Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s change in ar.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s change in AR?: Rapport Therapeutics, Inc. (RAPP) reported change in AR of $58K in Q1 2026.
What does change in AR mean?: Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.